Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2004

View Archived Issues

Novel NMDA antagonists may protect neurons from ischemia-induced cell death

Phase I/II trial of human papillomavirus vaccine

Genentech reviews Q2 developments

Endothelin receptor antagonist attenuates diabetes-induced endothelial lesions

Menarini reports a new class of NK2 antagonists with potential as analgesic agents

New 5-HT6 antagonist with improved pharmacokinetic properties designed at GSK

A cyanoguanidine-based prodrug identified as a clinical candidate by Leo scientists

Endo acquires North American rights to Rapinyl

New modafinil formulation shows promise for children with ADHD

New antidiabetic agents in early development at Bayer

Novel SGLT2 inhibitors prepared and tested at Kissei

Bayer scientists design new MKK4 and/or MKK7 inhibitors

New antiobesity agents disclosed by Bayer in a recent patent

Boehringer Ingelheim claims novel factor Xa inhibitors

New inhibitors of ICAM-1/LFA-1-mediated cell adhesion and their use

New cannabinoid CB1 antagonist for use in obesity, cognitive disorders, etc.

ProIX obtains development and marketing rights for novel PI-3K inhibitors

Antiretroviral effects of statins indicate potential in HIV infection

Viragen updates Multiferon progress

Liprostin successfully completes phase II study in peripheral vascular disease

Alimta approved for second-line treatment of advanced lung cancer

Canadian approval for phase I study of Proxinium

Sanofi-Aventis is world's third largest pharma company

European MAA submission for clofarabine for pediatric leukemias

Orphan drug status for HuMax-CD4

Kyorin and Merck conclude license agreement

Zeria targets launches after 2006

Novel back-up candidate with vasopressin antagonist activity identified at Yamanouchi

Results of efficacy and pharmacokinetic studies of an anxiolytic prodrug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...